CTOs on the Move

Tricida

www.tricida.com

 
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.tricida.com
  • 7000 Shoreline Court Suite 201
    South San Francisco, CA USA 94080
  • Phone: 415.429.7800

Executives

Name Title Contact Details
Wilhelm Stahl
Chief Technology Officer Profile

Funding

Tricida raised $55M on 07/26/2016
Tricida raised $57.5M on 11/08/2017
Tricida raised $100M on 03/02/2018

Similar Companies

Cadila Pharmaceuticals - CPL

Cadila Pharmaceuticals - CPL, Inc. is a Chesterfield, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immune Pharmaceuticals

Immune Pharmaceuticals is developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.

Hoodia Products

Hoodia Products is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vitality Biopharma

Vitality has developed a new class of cannabinoid prodrugs (cannabosides), which enable selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable potent local therapeutic effects while reducing or avoiding the systemic delivery of THC to the brain. Currently, the psychoactivity of THC limits the dose of cannabinoids that can be used for treatment of pain and inflammation. Studies have shown that the cannabinoid system is a potent mediator of pain relief and inflammation, as studies have shown that cannabinoid drugs can in some cases be far more potent than opiates for pain relief, and far more potent than aspirin or corticosteroids for providing anti-inflammatory effects. For example, cannabinoid drugs have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. Studies have also shown they can be 20 times as potent as aspirin, and twice as potent as corticosteroids for treating inflammation. But currently, the “elephant in the room” remains, which is that the desired potent effects cannot be achieved when high doses of THC enter the bloodstream and brain. Patients are forced to limit their doses, so targeted administration is critical. Our solution goes to the heart of this issue and offers an alternative means to increase the beneficial dosage, right at the site of disease – where it matters most, and relegates the psychoactive nature of the drug to a manageable side effect.